Revolution Medicines, Inc. $RVMD Shares Sold by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. decreased its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 20.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 797,455 shares of the company’s stock after selling 200,000 shares during the quarter. Revolution Medicines comprises about 1.7% of Frazier Life Sciences Management L.P.’s investment portfolio, making the stock its 15th biggest position. Frazier Life Sciences Management L.P.’s holdings in Revolution Medicines were worth $63,517,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in RVMD. Indiana Trust & Investment Management Co purchased a new position in shares of Revolution Medicines in the 4th quarter worth $32,000. Global Retirement Partners LLC raised its position in shares of Revolution Medicines by 1,002.8% in the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after buying an additional 361 shares during the period. Torren Management LLC purchased a new position in shares of Revolution Medicines in the 4th quarter worth $33,000. Arax Advisory Partners purchased a new position in shares of Revolution Medicines in the 4th quarter worth $38,000. Finally, Darwin Wealth Management LLC purchased a new position in shares of Revolution Medicines in the 4th quarter worth $40,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on RVMD shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a research report on Tuesday, April 21st. UBS Group started coverage on Revolution Medicines in a research report on Friday, February 27th. They issued a “buy” rating on the stock. Piper Sandler increased their target price on Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a research report on Monday, June 1st. Finally, Stifel Nicolaus reaffirmed a “buy” rating on shares of Revolution Medicines in a research report on Monday, April 20th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $123.72.

Insider Activity at Revolution Medicines

In other news, CFO Jack Anders sold 2,753 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $273,868.44. Following the completion of the sale, the chief financial officer directly owned 125,512 shares in the company, valued at $12,485,933.76. This trade represents a 2.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Margaret A. Horn sold 4,583 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $455,916.84. Following the sale, the chief operating officer owned 157,570 shares of the company’s stock, valued at $15,675,063.60. This represents a 2.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 148,592 shares of company stock valued at $20,855,132. 7.60% of the stock is currently owned by insiders.

Revolution Medicines Stock Up 3.1%

Shares of Revolution Medicines stock opened at $153.87 on Friday. The business has a 50-day moving average of $140.76 and a 200-day moving average of $110.42. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80. The company has a market capitalization of $32.71 billion, a PE ratio of -21.76 and a beta of 1.40. Revolution Medicines, Inc. has a 1-year low of $34.00 and a 1-year high of $166.50.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same quarter in the prior year, the business posted ($1.13) earnings per share. As a group, equities analysts forecast that Revolution Medicines, Inc. will post -7.94 EPS for the current fiscal year.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.